Table 3.
Cox proportional hazards regression analysis based on several prognostic variables, showing p-values, hazard ratios, and 95% confidence intervals.
| Variables | Hazard Ratio | 95% CI of Hazard Ratio | p-Value |
|---|---|---|---|
| Univariate analysis | |||
| cfDNA copies/mL * | 1.02 | 1.0–1.03 | 0.054 |
| cf-mtDNA copies/mL * | 1.01 | 1.0–1.02 | 0.009 |
| Age * | 0.99 | 0.97–1.03 | 0.76 |
| Gender ^ | 0.68 | 0.34–1.37 | 0.276 |
| HNSCC site ^ | 1.54 | 0.85–2.79 | 0.153 |
| TNM stage ^ | 0.63 | 0.25–1.59 | 0.328 |
| Smoking status ^ | 1.24 | 0.56–2.27 | 0.744 |
| Duration of smoking * | 1.0 | 0.98–1.13 | 0.732 |
| Chemotherapy ^ | 1.17 | 0.63–2.17 | 0.632 |
| Radiotherapy ^ | 1.68 | 0.93–3.02 | 0.086 |
| Multivariate analysis | |||
| cfDNA copies/mL * | 1.02 | 1.0–1.04 | 0.013 |
| Cf-mtDNA copies/mL * | 1.01 | 1.0–1.02 | 0.002 |
| Age * | 0.99 | 0.95–1.03 | 0.691 |
| Gender ^ | 0.66 | 0.29–1.49 | 0.321 |
| HNSCC site ^ | 0.52 | 0.26–1.03 | 0.059 |
| TNM stage ^ | 0.44 | 0.19–0.98 | 0.045 |
| Smoking status ^ | 0.64 | 0.11–3.59 | 0.612 |
| Duration of smoking * | 1.01 | 0.97–1.05 | 0.6 |
| Chemotherapy ^ | 1.71 | 0.69–4.22 | 0.243 |
| Radiotherapy ^ | 0.39 | 0.17–0.93 | 0.063 |
* Continuous variable; ^ categorical variable gender, male vs. female; HNSCC site, oral vs. laryngeal; TNM stage, stage IV vs. other stages; smoking status, smokers vs. non-smokers; chemotherapy, received vs. did not receive; radiotherapy, received vs. did not receive.